Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

[1]  Gianni Amisano,et al.  Analysis of Variance , 2021, Applied Engineering Statistics.

[2]  R. Amaravadi,et al.  Targeting autophagy in cancer , 2018, Cancer.

[3]  N. Lisiak,et al.  Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment. , 2018, Current cancer drug targets.

[4]  Y. Yen,et al.  Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer , 2017, Clinical Cancer Research.

[5]  M. Herlyn,et al.  Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma , 2017, Oncotarget.

[6]  Wenxian Wu,et al.  Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. , 2017, Urologic oncology.

[7]  O. Tawfik,et al.  Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. , 2017, Cancer research.

[8]  Julia M. Hill,et al.  Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism , 2017, Nature Communications.

[9]  E. Demidenko,et al.  Autophagy promotes escape from phosphatidylinositol 3‐kinase inhibition in estrogen receptor‐positive breast cancer , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  R. Xavier,et al.  Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9. , 2017, Cell reports.

[11]  Z. Qian,et al.  VPS34 stimulation of p62 phosphorylation for cancer progression , 2017, Oncogene.

[12]  A. Schober,et al.  Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance , 2017, Cell Death & Disease.

[13]  M. Tschan,et al.  Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism , 2017, Molecular Cancer Therapeutics.

[14]  R. Amaravadi,et al.  Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors , 2017, International journal of molecular sciences.

[15]  P. Codogno,et al.  Phosphatidylinositol‐3‐phosphate in the regulation of autophagy membrane dynamics , 2017, The FEBS journal.

[16]  D. Waugh.  Expanding the Armamentarium for Castrate-resistant Prostate Cancer. , 2017, European urology.

[17]  Terje Johansen,et al.  Microenvironmental autophagy promotes tumour growth , 2017, Nature.

[18]  P. Codogno,et al.  Autophagy: A Druggable Process. , 2017, Annual review of pharmacology and toxicology.

[19]  B. Teh,et al.  Dual modulation of MCL-1 and mTOR determines the response to sunitinib , 2017, The Journal of clinical investigation.

[20]  J. Pereira-Leal,et al.  Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer? , 2016, Current cancer drug targets.

[21]  A. Tinker,et al.  Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma , 2016, Molecular Cancer Research.

[22]  E. White,et al.  Recent insights into the function of autophagy in cancer , 2016, Genes & development.

[23]  A. Shisheva,et al.  Active vacuolar H+ ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency. , 2016, American journal of physiology. Cell physiology.

[24]  Ahmed Negida,et al.  Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis. , 2016, Breast disease.

[25]  H. Iwata,et al.  Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy , 2016, BMC Cancer.

[26]  P. Finan,et al.  Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo. , 2016, ACS medicinal chemistry letters.

[27]  R. Amaravadi,et al.  Emerging strategies to effectively target autophagy in cancer , 2016, Oncogene.

[28]  C. Arteaga,et al.  Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers , 2015, Breast Cancer Research.

[29]  R. Bueno,et al.  Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models , 2015, PloS one.

[30]  J. Bergh,et al.  Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer , 2015, Molecular oncology.

[31]  Seamus J. Martin,et al.  Autophagy in malignant transformation and cancer progression , 2015, The EMBO journal.

[32]  G. Stark,et al.  Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs , 2015, International journal of cancer.

[33]  O. Kallioniemi,et al.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation , 2015, Nature.

[34]  L. weiswald,et al.  Spherical Cancer Models in Tumor Biology1 , 2015, Neoplasia.

[35]  M. Mathieu,et al.  A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. , 2014, Nature chemical biology.

[36]  A. Vincent-Salomon,et al.  Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers , 2014, Autophagy.

[37]  John A. Tallarico,et al.  Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo , 2014, Nature Cell Biology.

[38]  A. Thorburn,et al.  Targeting autophagy in breast cancer. , 2014, World journal of clinical oncology.

[39]  Michael Ghannam,et al.  Bioequivalence of a New Generic Formulation of Erlotinib Hydrochloride150 mg Tablets versus Tarceva in Healthy Volunteers under FastingConditions , 2014 .

[40]  R. Clarke,et al.  Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer , 2014, Clinical Cancer Research.

[41]  Krister Wennerberg,et al.  Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.

[42]  A. Lluch,et al.  Emerging EGFR antagonists for breast cancer , 2014, Expert opinion on emerging drugs.

[43]  A. Thorburn,et al.  Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. , 2014, Cancer discovery.

[44]  A. Thorburn,et al.  STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. , 2014, Cancer research.

[45]  Jukka Westermarck,et al.  ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays , 2014, PloS one.

[46]  M. Herlyn,et al.  Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. , 2014, The Journal of clinical investigation.

[47]  S. Linder,et al.  Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine , 2014, Autophagy.

[48]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[49]  A. Goldhirsch,et al.  Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. , 2013, Breast.

[50]  M. Jäättelä,et al.  Sunitinib and SU11652 Inhibit Acid Sphingomyelinase, Destabilize Lysosomes, and Inhibit Multidrug Resistance , 2013, Molecular Cancer Therapeutics.

[51]  S. Ryter,et al.  Autophagy in human health and disease. , 2013, The New England journal of medicine.

[52]  J. Ou,et al.  Effects of Lipofectamine 2000/siRNA Complexes on Autophagy in Hepatoma Cells , 2012, Molecular Biotechnology.

[53]  P. Marks,et al.  Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death , 2012, Proceedings of the National Academy of Sciences.

[54]  R. Greil,et al.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  P. Codogno,et al.  Canonical and non-canonical autophagy: variations on a common theme of self-eating? , 2011, Nature Reviews Molecular Cell Biology.

[56]  O. Kepp,et al.  Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study , 2011, Oncogene.

[57]  N. Mizushima,et al.  The role of Atg proteins in autophagosome formation. , 2011, Annual review of cell and developmental biology.

[58]  G. Peters,et al.  Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance , 2011, Clinical Cancer Research.

[59]  Yi Shen,et al.  pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation. , 2010, Cancer research.

[60]  L. Kunz-Schughart,et al.  Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.

[61]  K. Eng,et al.  A novel quantitative flow cytometry-based assay for autophagy , 2010, Autophagy.

[62]  K. Kern,et al.  Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Jäättelä,et al.  Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux , 2009, Autophagy.

[64]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[65]  Katherine S Panageas,et al.  A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[66]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Deberardinis,et al.  Autophagy in metazoans: cell survival in the land of plenty , 2005, Nature Reviews Molecular Cell Biology.

[68]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[69]  S. Kain,et al.  An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. , 1996, Analytical biochemistry.

[70]  B. Teicher,et al.  Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[71]  W. C. Guenther,et al.  Analysis of variance , 1968, The Mathematical Gazette.

[72]  S. Pedersen,et al.  Additional file 5: Figure S5. of Roles of acid-extruding ion transporters in regulation of breast cancer cell growth in a 3-dimensional microenvironment , 2016 .

[73]  Lee,et al.  Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 , 2016 .

[74]  B. Pasquier.  Autophagy inhibitors , 2015, Cellular and Molecular Life Sciences.

[75]  Juergen Friedrich,et al.  Spheroid-based drug screen: considerations and practical approach , 2009, Nature Protocols.